Working... Menu

iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients (IDENTIFY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03364257
Recruitment Status : Recruiting
First Posted : December 6, 2017
Last Update Posted : March 21, 2019
Information provided by (Responsible Party):

Brief Summary:
Prospective, multicentre French observational study assessing the performance and medico-economic utility of iDTECT Blood versus conventional microbiologic diagnosis in patients with febrile neutropenia

Condition or disease Intervention/treatment
Febrile Neutropenia Acute Leukemia Stem Cell Transplantation Infection Diagnostic Test: iDTECT Blood

Detailed Description:
Febrile neutropenic patients suspected of sepsis will follow the conventional infectious diagnosis work-up over the entire observation period, and will be tested in addition with iDTECT Blood on Study Day 1.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 97 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: National, Single-arm Clinical Study on iDTECT™ Blood Performance to Identify Viral or Bacterial Pathogens in Febrile Neutropenic Patients With Suspected Infection
Actual Study Start Date : May 18, 2018
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : May 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever

Intervention Details:
  • Diagnostic Test: iDTECT Blood
    Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples

Primary Outcome Measures :
  1. Rate of detection of clinically relevant bacterial or viral pathogen (CRBV) by iDTECT™ Blood as compared to conventional microbiological methods at inclusion [ Time Frame: 7 months ]
    Sensitivity, specificity, negative predictive value, positive predictive value at inclusion

Secondary Outcome Measures :
  1. Antiobiotic use [ Time Frame: 9 months ]
    Type of antibiotic, duration of antibiotic course

Biospecimen Retention:   Samples With DNA
Whole blood and plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients treated with chemotherapy for Acute Leukaemia (AL) or Myelodysplastic Syndrome (MDS) or in the context of hematopoietic stem cell transplantation (HSCT), presenting a febrile neutropenic episode and suspected of infection

Inclusion Criteria:

  1. Age > 5 years and weight > 16 Kg
  2. Patients having signed the written study informed consent form (ICF) prior to any study-mandated procedure. For children/adolescents: ICF obtained from both children's parents/ legal representative prior to any study-mandated procedure, and in addition for adolescents (13-17 years): assent form to be signed
  3. Patient presenting severe neutropenia (absolute neutrophil count < 0.5 Giga/L) anticipated to be long lasting (> 10 days) following intensive chemotherapy for acute myeloid or lymphoid leukaemia (AML or ALL) or myelodysplastic syndrome or in the context of hematopoietic stem cells transplantation
  4. Febrile episode (oral temperature > 38.3°C once, or 2 measures > 38.0°C taken 2h apart).

Exclusion Criteria:

  1. Known HIV infection or AIDS diagnosis
  2. Already microbiologically confirmed infection
  3. Patient status preventing the study test to be performed
  4. Patient with an obvious infectious disease diagnosis requiring minimal additional microbiological documentation or confirmation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03364257

Layout table for location contacts
Contact: Dangles +33687137695

Layout table for location information
Hospital Necker Recruiting
Paris, France
Contact: Blanche, Prof, MD         
Hospital Robert Debré Recruiting
Paris, France
Contact: Baruchel, Prof, MD         
Hospital Salpétrière Recruiting
Paris, France
Contact: Souchet, MD         
Hospital Trousseau Recruiting
Paris, France
Contact: Petit, Prof, MD         
Hosptial Saint Louis Recruiting
Paris, France
Contact: Le Goff, MD         
Principal Investigator: Socié, Prof, MD         
Principal Investigator: Thieblemont, Prof, MD         
Principal Investigator: Raffoux, MD         
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Pathoquest Identifier: NCT03364257     History of Changes
Other Study ID Numbers: PTQ-02
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: March 21, 2019
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pathoquest:

Additional relevant MeSH terms:
Layout table for MeSH terms
Febrile Neutropenia
Leukocyte Disorders
Hematologic Diseases
Body Temperature Changes
Signs and Symptoms